Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx is expected to experience positive catalysts in the future, including a potential increase in same-store productivity, continued expansion into new U.S. treating centers, and resumption of sales in China. Additionally, the completion of enrollment in the AeriSeal Convert II trial could significantly expand the addressable market, while strategic deployment of LungTraX Detect may also support better patient identification. Despite a decline in revenue in the last quarter, Pulmonx showed evidence of stabilization with improved gross margin, decreased operating expenses, and a strong cash position. These factors suggest a positive outlook for the company's future performance.

Pulmonx is facing a decline in revenue due to disruptions in US sales and the absence of China sales while awaiting registration renewal, leading to a net loss. The leadership reset and emphasis on sales force productivity and cost control aim to improve execution and commercial focus, but the success of these efforts remains uncertain, with the company needing a strong Q4 performance to rebuild investor confidence. However, there are significant risks, including clinical and regulatory challenges, partnership and financial risks, and the potential for continued weakness in the market.